진통제 시장 평가 : 약물 종류별, 투여 경로별, 용도별, 유통 채널별, 지역별 기회 및 예측(2017-2031년)

Global analgesics market is projected to witness a CAGR of 6.16% during the forecast period 2024-2031, growing from USD 37.42 billion in 2023 to USD 60.37 billion in 2031. The rising requirement for analgesics can be attributed to the rapid growth of the geriatric population, increasing incidences of chronic diseases and disorders, and the growing requirement for surgical intervention for treating various conditions. The rising requirement for different surgical procedures, including hysterectomies, to ensure the health and well-being of patients and aid them in returning to their daily activities with ease is one of the major factors augmenting the global analgesics market demand to manage surgery-related pain. Abdominal hysterectomy is the most common gynecological surgery performed in the United States.

Furthermore, the rising prevalence of chronic diseases and disorders is also boosting the global analgesics market growth. Patients suffering from chronic conditions that often are lifelong prefer non-invasive alternatives to effectively manage their pain due to the frequent requirement of appropriate therapies. Non-invasive pain relief methods provide ease of use to the patients, which is vital in cases where the patients might require frequent pain relief. Meanwhile, the growth of the geriatric population is also propelling the demand for the analgesics market, as the older population is more prone to falling ill and getting injured due to lack of coordination.

Additionally, the government and regulatory bodies across the globe are increasingly working on boosting the development of non-opioid alternatives for opioid-based analgesics that have been traditionally used for managing pain in cases of surgeries and chronic health conditions, positively influencing the market's expansion by ensuring the increased availability of non-opioid analgesics. In February 2022, the U.S. Food and Drug Administration (FDA) unveiled new steps to foster the development of alternatives to opioids that are non-addictive for decreasing exposure to opioids and managing acute pain. As part of the United States Department of Health and Human Services' Five-Point Strategy to combat the opioid crisis, the FDA is addressing the epidemic on all fronts and significantly focusing on preventing new addictions and decreasing exposure to opioids by taking measures to encourage appropriate prescribing and promoting the development of improved pain relief solutions.

Increasing Cases of Chronic Conditions Boost Market Demand

The rising cases of chronic diseases and injuries are one of the major factors propelling the requirement for different types of analgesics. As per the estimates of the Christopher & Dana Reeve Foundation, approximately 18,000 new cases of spinal cord injury are reported in the United States every year. This increase in cases of spinal cord injuries is augmenting the requirement for various pain management solutions, including analgesics. Neuropathic or nerve pain is most common in cases of spinal cord injuries and is often described as a tight, burning, aching, or squeezing pain. Additionally, patients with spinal cord injuries also often suffer from musculoskeletal pain in the area above the injury, thus increasing the reliance on analgesics for pain relief. Moreover, the rising cases of cancer, among other chronic diseases, are also increasing the requirement for analgesics. Individuals with cancer experience pain due to the cancer treatment, the cancer itself, or a combination of both. Pain can arise from varying sources, and the pain relief offered depends upon the severity and type of pain, along with the general level of fitness and health of the patient. In cases of severe cancer pain, fast-acting opioids, fentanyl, or morphine are commonly used.

Rising Requirement for Surgical Procedures Supports Market Expansion

The growing requirement for surgical procedures for treating and managing various health conditions is boosting the requirement for different types of analgesics to manage postoperative pain. The estimated increase in the requirement for surgical procedures can be attributed to increasing incidences of road traffic accidents, metabolic diseases, and rising cases of cardiovascular disorders. According to the estimates of the U.S. Centers for Disease Control and Prevention, in 2022, approximately 702,880 people died from heart disease in the United States. This increase and the severe nature of the condition are augmenting the requirement for surgical interventions and propelling the reliance on analgesics for managing surgical pain. Postoperative pain control aids patients in transitioning smoothly back to their normal functions and is essential for reducing the various negative consequences associated with acute postsurgical pain, thus increasing the requirement for opioid analgesics and providing lucrative growth opportunities to the market.

Traditionally, opioid analgesic therapy has been used for treating acute postoperative pain. However, concerns about the misuse of opioids are bolstering the demand for research activities to support the development of pain treatment strategies that focus on using a multimodal pain management approach.

Retail Pharmacies Hold Significant Market Share

The expansion of the segment can be attributed to the increasing generation of prescriptions for analgesics due to the growing prevalence of chronic conditions, increasing cases of injuries, and rapid growth of the geriatric population. Additionally, the increasing launch of over-the-counter (OTC) analgesics contributes to the significant presence of retail pharmacies.

Meanwhile, online pharmacies are expected to witness significant growth over the forecast period due to the different advantages they offer, including lucrative discounts, home delivery, and overnight shipping. Additionally, various online pharmacies are working on increasing the availability of same-day delivery services, further supporting the segment's expansion. In October 2024, Amazon Pharmacy of Amazon.com, Inc. announced their plans to double the number of cities where patients can get their medications on the same day. With the help of its advanced automation technology and vast logistics network, the company aims to solve some of the biggest issues of the pharmacy sector: affordable access to medications and lack of convenience.

North America Holds Major Market Share

The growth of the North American analgesics market can be attributed to the strong presence of key players in the region, the growth of the geriatric population, and rising cancer cases. As per the estimates of the National Cancer Institute, 2,001,140 new cases of cancer are expected to be diagnosed in the United States in 2024. This increase is propelling the requirement for analgesics in the country among cancer patients to manage the different types of cancer-related pains. Mild cancer pain is usually treated with non-opioid analgesics alone or in combination with opioids, whereas moderate to severe cancer pain is treated with strong opioids. Additionally, the growth of the market is supported by rising research and development activities that aim to create safer and more effective pain management therapies. The United States has been at the forefront of innovation, with a wide range of pharmaceutical companies in the country significantly investing in the development of novel drug delivery systems and non-opioid analgesics. Additionally, the increasing awareness about the different analgesics available for individuals living with chronic health conditions and growing efforts of the regulatory bodies in North America to increase the availability of non-opioid analgesics are also providing lucrative growth opportunities to the market.

Future Market Scenario (2024-2031F)

As per the global analgesics market analysis, the market is expected to witness significant growth over the forecast period due to rising cases of chronic diseases, increasing requirements for surgical intervention, and expansion of the geriatric population. The World Health Organization (WHO) estimates that by 2030, one in six people across the globe will be 60 or older. This growth is expected to propel the market's demand as the older population is more prone to getting sick and requires analgesics to manage pain. Furthermore, the advancements in drug delivery systems and increasing efforts to develop non-opioid pain medications are also expected to provide lucrative growth opportunities to the market.

Additionally, the demand for non-opioid analgesics is also expected to increase significantly in the coming years due to the global opioid crisis, because of which healthcare professionals are working on reducing opioid prescriptions. Regulatory bodies and governments are also supporting the efforts of pharmaceutical companies to innovate and develop new non-opioid formulations, providing lucrative growth opportunities to the market. Meanwhile, the rise in disposable incomes and growing awareness about the various options available for pain management are also expected to drive the demand for analgesics in different regions across the globe.

Key Players Landscape and Outlook

The market's key players are focusing on developing and launching new products to expand their market share. In March 2023, Pfizer Inc. announced that they had received approval from the U.S. FDA for ZAVZPRET, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray used for treating migraine. This approval marks a significant breakthrough for patients suffering from migraine who require freedom from pain to carry out their day-to-day tasks and prefer alternatives to oral medications. The introduction of the product also underscores the company's commitment to delivering novel treatment options to ensure patients with migraine receive relief. Such efforts are expected to aid the company in expanding its product portfolio and providing novel therapeutic solutions to patients worldwide.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Analgesics Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug Class
    • 4.2.1.1. Opioid
    • 4.2.1.2. Non-opioid
    • 4.2.1.3. Compound Medication
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Oral
    • 4.2.2.2. Parenteral
    • 4.2.2.3. Topical
    • 4.2.2.4. Transdermal
    • 4.2.2.5. Others
  • 4.2.3. By Application
    • 4.2.3.1. Musculoskeletal Pain
    • 4.2.3.2. Dental Pain
    • 4.2.3.3. Surgical Pain
    • 4.2.3.4. Cancer Pain
    • 4.2.3.5. Neuropathic Pain
    • 4.2.3.6. Others
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Hospital Pharmacies
    • 4.2.4.2. Retail Pharmacies
    • 4.2.4.3. Online Pharmacies
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Drug Class
  • 4.3.2. By Route of Administration
  • 4.3.3. By Application
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. North America Analgesics Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. Opioid
    • 5.2.1.2. Non-opioid
    • 5.2.1.3. Compound Medication
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Parenteral
    • 5.2.2.3. Topical
    • 5.2.2.4. Transdermal
    • 5.2.2.5. Others
  • 5.2.3. By Application
    • 5.2.3.1. Musculoskeletal Pain
    • 5.2.3.2. Dental Pain
    • 5.2.3.3. Surgical Pain
    • 5.2.3.4. Cancer Pain
    • 5.2.3.5. Neuropathic Pain
    • 5.2.3.6. Others
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Analgesics Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Drug Class
        • 5.3.1.2.1.1. Opioid
        • 5.3.1.2.1.2. Non-opioid
        • 5.3.1.2.1.3. Compound Medication
      • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.2.1. Oral
        • 5.3.1.2.2.2. Parenteral
        • 5.3.1.2.2.3. Topical
        • 5.3.1.2.2.4. Transdermal
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Application
        • 5.3.1.2.3.1. Musculoskeletal Pain
        • 5.3.1.2.3.2. Dental Pain
        • 5.3.1.2.3.3. Surgical Pain
        • 5.3.1.2.3.4. Cancer Pain
        • 5.3.1.2.3.5. Neuropathic Pain
        • 5.3.1.2.3.6. Others
      • 5.3.1.2.4. By Distribution Channel
        • 5.3.1.2.4.1. Hospital Pharmacies
        • 5.3.1.2.4.2. Retail Pharmacies
        • 5.3.1.2.4.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Analgesics Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Analgesics Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Analgesics Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Analgesics Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Clinical Trials
• 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. AbbVie Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 21.3.2. Pfizer Inc.
  • 21.3.3. Endo, Inc.
  • 21.3.4. Eli Lilly and Company
  • 21.3.5. Bayer AG
  • 21.3.6. Abbott Laboratories
  • 21.3.7. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
  • 21.3.8. GlaxoSmithKline plc
  • 21.3.9. Teva Pharmaceutical Industries Ltd.
  • 21.3.10. Groupe Sanofi

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer